Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells $20,835.00 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen sold 500 shares of Amphastar Pharmaceuticals stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $41.67, for a total value of $20,835.00. Following the transaction, the director now directly owns 78,833 shares of the company’s stock, valued at $3,284,971.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Amphastar Pharmaceuticals Stock Performance

Amphastar Pharmaceuticals stock opened at $42.46 on Friday. The stock has a 50-day simple moving average of $43.48 and a 200 day simple moving average of $50.75. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of 16.46, a P/E/G ratio of 1.02 and a beta of 0.85. The company has a quick ratio of 1.70, a current ratio of 2.17 and a debt-to-equity ratio of 0.92. Amphastar Pharmaceuticals, Inc. has a 12-month low of $35.93 and a 12-month high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing the consensus estimate of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The company had revenue of $178.11 million during the quarter, compared to analyst estimates of $174.90 million. On average, research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on AMPH shares. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, April 10th. StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 target price for the company. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $66.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. YHB Investment Advisors Inc. acquired a new position in shares of Amphastar Pharmaceuticals during the first quarter valued at $27,000. McGlone Suttner Wealth Management Inc. acquired a new position in Amphastar Pharmaceuticals during the 4th quarter valued at about $28,000. Principal Securities Inc. acquired a new position in Amphastar Pharmaceuticals during the 4th quarter valued at about $34,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Amphastar Pharmaceuticals by 99.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock valued at $58,000 after purchasing an additional 628 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its position in shares of Amphastar Pharmaceuticals by 27.8% during the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after buying an additional 223 shares during the period. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.